HURA Stock Forecast: TuHURA Biosciences, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.36
−0.73% on the day

The median 12-month analyst price target for TuHURA Biosciences, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 18 Nov 2026 — in the weakest quartile.

Market cap
$89.2M
Ticker Nerd rank
24/ 100
Median analyst target
$8.00
Analysts covering
4
Revenue$0.0
Operating income−$8.8M
Net income−$9.2M
Free cash flow−$8.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−6.2%
1M
−23.6%
YTD
+79.7%
1Y
−22.3%
From 52W high
−56.8%
From 52W low
+209.1%
$0.44
$3.15
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores TuHURA Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
73
Revisions
64
Accruals
39
Quality
27
Momentum
24
Growth
20
Volatility
15
Issuance
4

Value (73): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

HURA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HURA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26HURAHigh $10.00Median $8.00Low $6.20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$6.20
Low
$8.00
Median
$10.00
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Nov 2026HC Wainwright & Co.ReiteratesBuy$10
27 Oct 2026HC Wainwright & Co.ReiteratesBuy$10
18 Aug 2026CitizensReiteratesMarket Outperform$9.00
27 Apr 2026CitizensInitiatesMarket Outperform$9.00
3 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025Maxim GroupMaintainsBuy—
16 May 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright & Co.MaintainsBuy—
3 Mar 2025HC Wainwright & Co.InitiatesBuy—
19 Dec 2024Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HURA.

Market Radar

This page is one stock. Monday covers all of them.

HURA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

HURA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, TuHURA Biosciences, Inc. returned −22.3% against +9.2% for the S&P 500, dividends included.

HURA vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Jan 26Apr 26Jul 26Oct 26HURAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HURA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
4.9×

Cheaper than 19% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−167.5%

Higher than 8% of US stocks

Return on assets
−60.4%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TuHURA Biosciences, Inc. has a market value of $89.2M and an enterprise value of $100.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$30.6M.

  • Free cash flow in the twelve months to 30 June 2026: −$29.9M.

  • TuHURA Biosciences, Inc. spent $8K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 63.7M.

  • TuHURA Biosciences, Inc. employs 22 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

HURA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
HURATuHURA Biosciences, Inc.$89.2M24
EQEquillium, Inc.$90.6M52
ANIXAnixa Biosciences, Inc.$90.9M61
ZURAZura Bio Ltd.$91.6M15
RANIRani Therapeutics Holdings, Inc.$88.4M63
PMVPPMV Pharmaceuticals, Inc.$92.1M59
VANIVivani Medical, Inc.$94.7M44

Take a look at HURA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own TuHURA Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about HURA

What is the HURA stock price forecast for 2026-2027?

The median 12-month analyst price target for TuHURA Biosciences, Inc. is $8, with estimates ranging from $6.2 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HURA stock a buy right now?

Of the 4 analysts covering TuHURA Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TuHURA Biosciences, Inc. 24 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HURA?

As at 18 Nov 2026, TuHURA Biosciences, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (73 of 100).

Will HURA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $8, and Ticker Nerd's factor model ranks TuHURA Biosciences, Inc. 24 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HURA stock forecast for 2030?

No analyst covering TuHURA Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HURA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.2 to $10 over the next 12 months.

How has HURA stock performed over the past year?

TuHURA Biosciences, Inc. returned -22.3% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TuHURA Biosciences, Inc. do?

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, including IFx-2.0, an innate immune agonist intended to enhance responses to checkpoint inhibitors, and additional technologies aimed at addressing both primary and acquired resistance in the tumor microenvironment.

Company

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company focused on developing novel therapies designed to overcome resistance to cancer immunotherapy. The company’s current pipeline centers on immune-modulating product candidates, including IFx-2.0, an innate immune agonist intended to enhance responses to checkpoint inhibitors, and additional technologies aimed at addressing both primary and acquired resistance in the tumor microenvironment. TuHURA Biosciences also works on personalized cancer vaccines and bi-functional antibody-drug conjugates that target immune-suppressing cells linked to treatment resistance. Based in Tampa, Florida, TuHURA Biosciences operates in the biotechnology and oncology drug development sectors, where its programs are intended to support combination approaches for difficult-to-treat cancers and advance late-stage clinical research in immunotherapy.

CEO Dr. James A. Bianco M.D. · 22 employees · United States · https://www.tuhurabio.com